Genetically Determined Inflammation‐Related Proteins in Asthma and Type‐2 Signatures

ABSTRACT Background Protein quantitative trait loci (pQTLs) remain underexplored in asthma but might provide valuable insights into the underlying molecular mechanisms. This study aimed to investigate associations between genetic variation and inflammation‐related plasma proteins and to assess diffe...

Full description

Saved in:
Bibliographic Details
Published inAllergy (Copenhagen) Vol. 80; no. 6; pp. 1702 - 1714
Main Authors Hernandez‐Pacheco, Natalia, Björkander, Sophia, Merid, Simon Kebede, Kere, Maura, Kumar, Ashish, Klevebro, Susanna, Mogensen, Ida, Ekström, Sandra, Janson, Christer, Palmberg, Lena, Hage, Marianne, Mälarstig, Anders, Merritt, Anne‐Sophie, Pershagen, Göran, Bergström, Anna, Kull, Inger, Schwenk, Jochen M., Melén, Erik
Format Journal Article
LanguageEnglish
Published Denmark Blackwell Publishing Ltd 01.06.2025
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABSTRACT Background Protein quantitative trait loci (pQTLs) remain underexplored in asthma but might provide valuable insights into the underlying molecular mechanisms. This study aimed to investigate associations between genetic variation and inflammation‐related plasma proteins and to assess differences in the levels of genetically determined proteins in subjects with signatures of type‐2 inflammation and/or asthma. Methods A pQTL mapping of 92 inflammation‐related plasma proteins was conducted in young adults from the Swedish BAMSE cohort (n = 1538). Replication of sentinel pQTLs was attempted, and the overlap and colocalization of pQTLs with expression quantitative trait loci (eQTLs) were investigated using publicly available data. Proteins with significant pQTLs were tested for association with type‐2 signatures defined as high levels of fractional exhaled nitric oxide, blood eosinophils, and/or sensitization to airborne allergens in subjects with or without asthma in BAMSE. Results Forty‐five sentinel pQTLs (33 cis, 12 trans) for 39 inflammation‐related proteins were identified (p ≤ 7.14 × 10−11), and a high proportion of these were validated in independent populations. A high likelihood for colocalization of cis‐pQTLs and cis‐eQTLs was observed for 19 proteins in different tissues. Six of the 39 circulating proteins with significant pQTLs were associated with type‐2 signatures and/or asthma, and matrix metalloproteinase‐10 (MMP‐10) showed the most significant associations. Conclusions These findings underscore the existence of a genetic component influencing the plasma levels of proteins involved in inflammatory processes, including MMP‐10, which is suggested to have a role in high type‐2 inflammation in asthma subjects. This study investigates the association between genetic variation and inflammation‐related plasma proteins, and the differences in the proteins genetically determined between subjects with type‐2 signatures and/or asthma. Our findings suggest a strong contribution of genetic variation to the inflammation‐related proteome. MMP‐10 was demonstrated to be involved in type‐2 signatures in young adults with and without asthma. BAMSE, Swedish abbreviation for Child (Barn), Allergy, Milieu, Stockholm, Epidemiology; bEos, blood eosinophils; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E against at least one common airborne allergen; MMP‐10, matrix metalloproteinase‐10; SNP, single nucleotide polymorphism.
Bibliography:This study was supported by grants from Vetenskapsrådet (2016‐03086; 2018‐02524; 2019‐01060; 2020‐02170); Forskningsrådet för hälsa, Arbetsliv och välfärd (2017‐00526); Formas (2016‐01646); Hjärt‐Lungfonden; the European Union (European Research Council, TRIBAL No 757919); Region Stockholm (ALF project); and the Asthma and Allergy Research Foundation. N.H.‐P. was supported with a Medium‐Term Research Fellowship by the European Academy of Allergy and Clinical Immunology (EAACI) and a Long‐Term Research Fellowship by the European Respiratory Society (ERS) (LTRF202101‐00861).
Funding
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Funding: This study was supported by grants from Vetenskapsrådet (2016‐03086; 2018‐02524; 2019‐01060; 2020‐02170); Forskningsrådet för hälsa, Arbetsliv och välfärd (2017‐00526); Formas (2016‐01646); Hjärt‐Lungfonden; the European Union (European Research Council, TRIBAL No 757919); Region Stockholm (ALF project); and the Asthma and Allergy Research Foundation. N.H.‐P. was supported with a Medium‐Term Research Fellowship by the European Academy of Allergy and Clinical Immunology (EAACI) and a Long‐Term Research Fellowship by the European Respiratory Society (ERS) (LTRF202101‐00861).
ISSN:0105-4538
1398-9995
1398-9995
DOI:10.1111/all.16608